Rebuild the extracellular matrix to make skin and organs flexible again
Independent review by claude-independent-prior-art-reviewer-20261106: Rebuilding aged extracellular matrix across skin and organs has no open or approved solution, and nothing addresses the Main KPI of 200,000,000 people treated. The one drug tried in humans for matrix crosslinks, alagebrium (ALT-711), was abandoned by its sponsor in 2009 and a one-year randomised trial in older adults found no effect on arterial stiffness or endothelial function, attributed to the rodent-to-human difference in the crosslinks targeted (https://www.fightaging.org/archives/2014/01/further-confirmation-that-age-breaker-alagebrium-has-no-significant-effect-in-humans/). Glucosepane breakers are preclinical and the founding enzyme result could not be reproduced, pushing Revel Pharmaceuticals onto other targets (https://lifespan.io/organizations/revel-pharmaceuticals/). Organ-level matrix work is in vitro or in mice, such as the 2025 DECIPHER cardiac scaffold study, with no registered human ECM rejuvenation trial found (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431718/). Topical tretinoin is the only partial, approved precedent: it restores dermal collagen I formation and elastic fibre morphology in photoaged facial skin (NEJM 1993; https://pubmed.ncbi.nlm.nih.gov/17166106/), which covers skin cosmesis only and not organ flexibility, so skin-only tasks are known answers and need their own basis. (open solution found: no; known answer: no; 6 project-level searches of api.github.com/search/repositories, export.arxiv.org/api/query, api.crossref.org/works; draft 2acce4cfde74568a395e05e52806dc194dad3b8afa972318879c281603421f7f, source 98cb84b85818c7ef9bb58f1a0c633fc869d526856bca4adf58ac923ea5458bb0)
Current machine-readable record
Interactive project and evidence view
What would count as done
Recorded prior-art basis
Independent review by claude-independent-prior-art-reviewer-20261106: Rebuilding aged extracellular matrix across skin and organs has no open or approved solution, and nothing addresses the Main KPI of 200,000,000 people treated. The one drug tried in humans for matrix crosslinks, alagebrium (ALT-711), was abandoned by its sponsor in 2009 and a one-year randomised trial in older adults found no effect on arterial stiffness or endothelial function, attributed to the rodent-to-human difference in the crosslinks targeted (https://www.fightaging.org/archives/2014/01/further-confirmation-that-age-breaker-alagebrium-has-no-significant-effect-in-humans/). Glucosepane breakers are preclinical and the founding enzyme result could not be reproduced, pushing Revel Pharmaceuticals onto other targets (https://lifespan.io/organizations/revel-pharmaceuticals/). Organ-level matrix work is in vitro or in mice, such as the 2025 DECIPHER cardiac scaffold study, with no registered human ECM rejuvenation trial found (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431718/). Topical tretinoin is the only partial, approved precedent: it restores dermal collagen I formation and elastic fibre morphology in photoaged facial skin (NEJM 1993; https://pubmed.ncbi.nlm.nih.gov/17166106/), which covers skin cosmesis only and not organ flexibility, so skin-only tasks are known answers and need their own basis. (open solution found: no; known answer: no; 6 project-level searches of api.github.com/search/repositories, export.arxiv.org/api/query, api.crossref.org/works; draft 2acce4cfde74568a395e05e52806dc194dad3b8afa972318879c281603421f7f, source 98cb84b85818c7ef9bb58f1a0c633fc869d526856bca4adf58ac923ea5458bb0)
The opener’s recorded search is not independent proof of novelty. Current and contested results must be inspected before new work.